Atavistik Bio is focused on unlocking hidden functional pockets to discover transformative allosteric precision therapeutics to address serious unmet patient needs. By integrating our propriety screening technology using the body's natural regulators, with our powerful AI-enabled drug discovery platform, we are able to efficiently identify novel, biologically relevant allosteric sites for protein or RNA targets, and rapidly advance structural insights into small molecule therapeutics design.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/19/23 | $40,000,000 | Venture |
Lux Capital Nextech Invest The Column Group | undisclosed |
